2Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum, 2003,48:1190-1199.
3Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med, 2003, 35:605-613.
4Abraham DJ, Vancheswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotie lung disease . Am J Pathol, 1997, 151:831-841.
5Shi-wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol, 2001,116:417-425.
6Braun-Moscovici Y, Nahir AM, Balbir-Gurman A. Endothelin and pulmonary arterial hypertension. Semin Arthritis Rheum, 2004, 34:442-453.
7Badesch DB, Bodin F, Channick RN, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Curr Thera Res, 2002,63:227-246.
8Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 2002,346:896-903.
9Cabane MH. Successful treatment of systemic scleraosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatol,2003,42:191-193.
10Liefeldt L, Giersbergen PL, Dingemanse J, et al. Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. Am J Kidney Dis, 2004, 43: 923-926.
